[go: up one dir, main page]

WO2004050848A3 - Methods for antigen masking of red blood cells resulting in reduced hemolysis - Google Patents

Methods for antigen masking of red blood cells resulting in reduced hemolysis Download PDF

Info

Publication number
WO2004050848A3
WO2004050848A3 PCT/US2003/038224 US0338224W WO2004050848A3 WO 2004050848 A3 WO2004050848 A3 WO 2004050848A3 US 0338224 W US0338224 W US 0338224W WO 2004050848 A3 WO2004050848 A3 WO 2004050848A3
Authority
WO
WIPO (PCT)
Prior art keywords
methods
rbc
blood cells
red blood
antigen masking
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/US2003/038224
Other languages
French (fr)
Other versions
WO2004050848A2 (en
Inventor
Adonis Stassinopoulos
Basha Clark
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Cerus Corp
Original Assignee
Cerus Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Cerus Corp filed Critical Cerus Corp
Priority to AU2003302499A priority Critical patent/AU2003302499A1/en
Publication of WO2004050848A2 publication Critical patent/WO2004050848A2/en
Publication of WO2004050848A3 publication Critical patent/WO2004050848A3/en
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0634—Cells from the blood or the immune system
    • C12N5/0641—Erythrocytes

Landscapes

  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Wood Science & Technology (AREA)
  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Biotechnology (AREA)
  • Zoology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Genetics & Genomics (AREA)
  • Microbiology (AREA)
  • Cell Biology (AREA)
  • Immunology (AREA)
  • Biochemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Hematology (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicinal Preparation (AREA)
  • Peptides Or Proteins (AREA)

Abstract

Methods are provided for the preparation of an RBC composition which has significantly reduced antigenicity. The methods of preparation of the red cell compositions involve the optimization of reaction conditions for attaching antigen masking compounds to the red cells without significantly affecting the function of the red cells, in particular reducing the hemolysis of the red cells from processing of the cells. The RBC compositions are of particular use for introduction into an individual in cases where the potential for an immune reaction is high, for example in alloimmunized blood recipients or in trauma situations where the possibility of transfusion of a mismatched unit of blood in higher. The RBC compositions of this invention provide a much lower risk of a transfusion associated immune reaction.
PCT/US2003/038224 2002-12-04 2003-12-03 Methods for antigen masking of red blood cells resulting in reduced hemolysis Ceased WO2004050848A2 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
AU2003302499A AU2003302499A1 (en) 2002-12-04 2003-12-03 Methods for antigen masking of red blood cells resulting in reduced hemolysis

Applications Claiming Priority (8)

Application Number Priority Date Filing Date Title
US43121602P 2002-12-04 2002-12-04
US43121402P 2002-12-04 2002-12-04
US43121302P 2002-12-04 2002-12-04
US43121502P 2002-12-04 2002-12-04
US60/431,213 2002-12-04
US60/431,215 2002-12-04
US60/431,214 2002-12-04
US60/431,216 2002-12-04

Publications (2)

Publication Number Publication Date
WO2004050848A2 WO2004050848A2 (en) 2004-06-17
WO2004050848A3 true WO2004050848A3 (en) 2004-12-09

Family

ID=32475715

Family Applications (4)

Application Number Title Priority Date Filing Date
PCT/US2003/038349 Ceased WO2004050897A2 (en) 2002-12-04 2003-12-03 Methods for preparing antigen masked red blood cells having reduced hemolysis by sera
PCT/US2003/038270 Ceased WO2004049914A2 (en) 2002-12-04 2003-12-03 Methods for reacting an antigen masking compound with red blood cells with high efficiency
PCT/US2003/038262 Ceased WO2004050029A2 (en) 2002-12-04 2003-12-03 Novel activated polyethylene glycol compounds
PCT/US2003/038224 Ceased WO2004050848A2 (en) 2002-12-04 2003-12-03 Methods for antigen masking of red blood cells resulting in reduced hemolysis

Family Applications Before (3)

Application Number Title Priority Date Filing Date
PCT/US2003/038349 Ceased WO2004050897A2 (en) 2002-12-04 2003-12-03 Methods for preparing antigen masked red blood cells having reduced hemolysis by sera
PCT/US2003/038270 Ceased WO2004049914A2 (en) 2002-12-04 2003-12-03 Methods for reacting an antigen masking compound with red blood cells with high efficiency
PCT/US2003/038262 Ceased WO2004050029A2 (en) 2002-12-04 2003-12-03 Novel activated polyethylene glycol compounds

Country Status (2)

Country Link
AU (4) AU2003298827A1 (en)
WO (4) WO2004050897A2 (en)

Cited By (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10799533B2 (en) 2015-10-23 2020-10-13 Cerus Corporation Plasma compositions and methods of use thereof
US11096963B2 (en) 2015-06-26 2021-08-24 Cerus Corporation Cryoprecipitate compositions and methods of preparation thereof
US11235090B2 (en) 2017-03-03 2022-02-01 Cerus Corporation Kits and methods for preparing pathogen-inactivated platelet compositions
US11554185B2 (en) 2017-12-29 2023-01-17 Cerus Corporation Systems and methods for treating biological fluids
US11883544B2 (en) 2019-06-28 2024-01-30 Cerus Corporation System and methods for implementing a biological fluid treatment device
US12011510B2 (en) 2019-06-22 2024-06-18 Cerus Corporation Biological fluid treatment systems
US12282015B2 (en) 2016-12-23 2025-04-22 Cerus Corporation Systems and methods for testing and screening using compound bound substrates

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7521174B2 (en) * 2003-12-05 2009-04-21 Albert Einstein College Of Medicine Of Yeshiva University Universal red blood cells, methods of preparing same, and uses thereof
CN102108119A (en) * 2009-12-25 2011-06-29 天津键凯科技有限公司 Multi-arm polyethylene glycol derivatives and their conjugates and gels with drugs
JP2025508550A (en) * 2022-03-07 2025-03-26 アイコート メディカル アクチエボラグ Novel Uses of PEG-Phospholipid Molecules

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6312685B1 (en) * 1998-03-13 2001-11-06 Timothy C. Fisher Red blood cells covalently bound with two different polyethylene glycol derivatives
WO2001091775A2 (en) * 2000-05-31 2001-12-06 Cerus Corporation Preparation of a pathogen inactivated solution of red blood cells having reduced immunogenicity

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NL292906A (en) * 1962-10-30

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6312685B1 (en) * 1998-03-13 2001-11-06 Timothy C. Fisher Red blood cells covalently bound with two different polyethylene glycol derivatives
WO2001091775A2 (en) * 2000-05-31 2001-12-06 Cerus Corporation Preparation of a pathogen inactivated solution of red blood cells having reduced immunogenicity

Cited By (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11096963B2 (en) 2015-06-26 2021-08-24 Cerus Corporation Cryoprecipitate compositions and methods of preparation thereof
US10799533B2 (en) 2015-10-23 2020-10-13 Cerus Corporation Plasma compositions and methods of use thereof
US12282015B2 (en) 2016-12-23 2025-04-22 Cerus Corporation Systems and methods for testing and screening using compound bound substrates
US11235090B2 (en) 2017-03-03 2022-02-01 Cerus Corporation Kits and methods for preparing pathogen-inactivated platelet compositions
US12064537B2 (en) 2017-03-03 2024-08-20 Cerus Corporation Kits and methods for preparing pathogen-inactivated platelet compositions
US11554185B2 (en) 2017-12-29 2023-01-17 Cerus Corporation Systems and methods for treating biological fluids
US12214092B2 (en) 2017-12-29 2025-02-04 Cerus Corporation Systems and methods for treating biological fluids
US12011510B2 (en) 2019-06-22 2024-06-18 Cerus Corporation Biological fluid treatment systems
US11883544B2 (en) 2019-06-28 2024-01-30 Cerus Corporation System and methods for implementing a biological fluid treatment device
US12343436B2 (en) 2019-06-28 2025-07-01 Cerus Corporation System and methods for implementing a biological fluid treatment device

Also Published As

Publication number Publication date
AU2003302499A8 (en) 2004-06-23
AU2003298827A1 (en) 2004-06-23
WO2004050029A3 (en) 2004-10-21
AU2003293237A1 (en) 2004-06-23
WO2004050029A2 (en) 2004-06-17
WO2004049914A3 (en) 2005-02-24
WO2004049914A2 (en) 2004-06-17
AU2003298827A8 (en) 2004-06-23
WO2004050897A3 (en) 2004-08-26
WO2004050897A2 (en) 2004-06-17
AU2003302499A1 (en) 2004-06-23
WO2004050848A2 (en) 2004-06-17
AU2003297614A1 (en) 2004-06-23
AU2003293237A8 (en) 2004-06-23
AU2003297614A8 (en) 2004-06-23

Similar Documents

Publication Publication Date Title
WO2003047650A3 (en) Preparation of red blood cells having reduced immunogenicity
WO2001074158A3 (en) Systems and methods for collecting leukocyte-reduced blood components, including plasma that is free or virtually free of cellular blood species
WO2001091775A3 (en) Preparation of a pathogen inactivated solution of red blood cells having reduced immunogenicity
EP2722387A3 (en) Definitive endoderm
AU9058091A (en) Preparation of nucleic acid samples
WO2004084825A3 (en) Wound healing composition derived from low platelet concentration plasma
WO2004050848A3 (en) Methods for antigen masking of red blood cells resulting in reduced hemolysis
MXPA05007888A (en) Autologous or homologous coagulant produced from anticoagulated whole blood.
WO2003076490A8 (en) Hydrophilic polymer derivate with y type branch and preparation method of it medical composite comprising above compound
MXPA06001821A (en) A stable liquid probiotic composition, preparation and applications thereof.
WO2005025615A3 (en) FACTOR IXa SPECIFIC ANTIBODIES DISPLAYING FACTOR VIIIa LIKE ACTIVITY
CA2407961A1 (en) Automated system and method for withdrawing compounds from blood
Matar et al. Down regulation of T-cell-derived IL-10 production by low-dose cyclophosphamide treatment in tumor-bearing rats restores in vitro normal lymphoproliferative response
WO2005021706A3 (en) Delivery of compounds with rehydrated blood cells
WO2003045427A3 (en) Pharmaceutical composition for inducing an immune response in a human or animal
WO2005030040A8 (en) Hematopoietic stem cell identification and isolation
WO2006023502A3 (en) Particle/cell separation device and compositions
WO2000044398A3 (en) Methods for increasing circulating platelets for collection and cryopreservation using thrombopoietin compositions
MY124727A (en) Tri-substituted phenyl derivatives and analogues.
AUPQ486699A0 (en) A method of treating infectious diseases
Haag-Weber et al. Impaired cellular host defence in peritoneal dialysis by two granulocyte inhibitory proteins
WO2003061611A3 (en) Long-life cosmetic composition comprising a pro-adhesive material and a separate dispersant compound
ES8301274A1 (en) Peptide antibiotic, component B, process for its preparation and its use in medicines.
GB2441094A (en) Methods for treatment and prevention of infection
WO2004041071A3 (en) Compositions, systems, and methods for focusing a cell-mediated immune response

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ OM PH PL PT RO RU SD SE SG SK SL TJ TM TN TR TT TZ UA UG US UZ VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): BW GH GM KE LS MW MZ SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IT LU MC NL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
122 Ep: pct application non-entry in european phase
NENP Non-entry into the national phase

Ref country code: JP

WWW Wipo information: withdrawn in national office

Country of ref document: JP